Equities Analysts Offer Predictions for Cencora Q1 Earnings

Cencora, Inc. (NYSE:COR - Free Report) - Stock analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for shares of Cencora in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings per share of $3.45 for the quarter, up from their prior forecast of $3.43. The consensus estimate for Cencora's current full-year earnings is $13.64 per share. Leerink Partnrs also issued estimates for Cencora's Q2 2025 earnings at $4.12 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.99 EPS, FY2027 earnings at $18.91 EPS and FY2028 earnings at $20.72 EPS.

Other equities analysts also recently issued research reports about the stock. Evercore ISI boosted their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research note on Thursday. StockNews.com cut Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Wells Fargo & Company increased their price target on Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a research report on Thursday, August 1st. Leerink Partners lowered their price objective on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research report on Monday, October 7th. Finally, UBS Group raised their target price on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a report on Thursday. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, Cencora presently has an average rating of "Moderate Buy" and an average price target of $271.20.

Cencora Stock Up 0.3 %

COR traded up $0.66 during trading hours on Friday, hitting $248.42. 1,376,047 shares of the company's stock were exchanged, compared to its average volume of 1,409,854. The firm has a market cap of $48.95 billion, a P/E ratio of 33.08, a price-to-earnings-growth ratio of 1.49 and a beta of 0.44. Cencora has a 12-month low of $191.11 and a 12-month high of $251.00. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The firm has a 50 day moving average of $231.95 and a 200 day moving average of $230.84.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.21 by $0.13. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm had revenue of $79.05 billion for the quarter, compared to analyst estimates of $77.68 billion.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be paid a dividend of $0.55 per share. This is a positive change from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date is Friday, November 15th. Cencora's dividend payout ratio (DPR) is currently 29.29%.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the firm's stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares of the company's stock, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cencora

Several large investors have recently modified their holdings of COR. New Millennium Group LLC purchased a new stake in Cencora in the 2nd quarter valued at $26,000. TCTC Holdings LLC purchased a new stake in shares of Cencora in the first quarter valued at about $29,000. TFO Wealth Partners LLC acquired a new stake in shares of Cencora during the first quarter worth about $30,000. MFA Wealth Advisors LLC purchased a new position in shares of Cencora during the second quarter worth about $30,000. Finally, Concord Wealth Partners acquired a new position in Cencora in the 3rd quarter valued at about $30,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.